| Status: Under consideration by AWMSG Scrutiny Panel | |
For the off-label treatment of recurrent low grade serous ovarian carcinoma (LGSOC) which has progressed following at least 1 previous platinum-based regimen. |
|
Medicine details |
|
| Medicine name | trametinib (Mekinist®) |
| Formulation | 2 mg film-coated tablets |
| Reference number | 6321 |
| Indication | As above |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 06/02/2025 |